SCHEDULE 13G/A: BlackRock Amends Passive Stake in Gilead Sciences, Reports 8.2% Beneficial Ownership
Beneficial Ownership Report
BlackRock, Inc. has filed an Amendment No. 16 to its Schedule 13G, disclosing a passive beneficial ownership of 8.2% in Gilead Sciences Inc. common stock as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 101,739,273 shares of Gilead Sciences Inc. common stock.
- This represents 8.2% of the total outstanding common shares of Gilead Sciences Inc.
- BlackRock holds sole voting power over 92,132,068 shares and sole dispositive power over 101,739,273 shares.
- No shared voting or dispositive power was reported.
- The filing is an Amendment No. 16 to a Schedule 13G, indicating a passive investment position.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- BlackRock Fund Managers Ltd, a subsidiary of BlackRock, Inc., beneficially owns 5% or greater of the outstanding shares of Gilead Sciences Inc.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing (Schedule 13G) reporting passive beneficial ownership. It does not contain information that would inherently convey positive or negative sentiment regarding the issuer's performance or outlook. The sentiment is neutral as it simply reports a holding.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by a major institutional asset manager, BlackRock, detailing its passive investment stake in a pharmaceutical company, Gilead Sciences. Such filings are common and reflect the ongoing portfolio management activities of large investment firms within the broader market.
Stakeholder Impact
- Shareholders: The disclosure of a significant passive stake by a major institutional investor like BlackRock can be viewed as a vote of confidence in the company's long-term prospects, potentially reassuring existing shareholders and attracting new ones.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the Power of Attorney by BlackRock, Inc. |
| 03/31/2025 | Date of event which requires the filing of this statement (reporting period end date). |
| 04/24/2025 | Date of signature for the Schedule 13G filing. |
Keywords
BlackRock, Gilead Sciences, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.